Abstract
The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxicities. The results of this study are compared to two similar phase II trials.
Publication types
-
Clinical Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / pathology
-
Drug Evaluation
-
Drugs, Investigational / administration & dosage
-
Drugs, Investigational / adverse effects
-
Drugs, Investigational / therapeutic use*
-
Female
-
Humans
-
Indazoles / administration & dosage
-
Indazoles / adverse effects
-
Indazoles / therapeutic use*
-
Middle Aged
-
Neoplasm Metastasis
Substances
-
Antineoplastic Agents
-
Drugs, Investigational
-
Indazoles
-
lonidamine